Abiopharma

🔍 Chen Tien-Szu (Executive)

Company: ASE Technology Holding Co., Ltd. (ASX)

Report Date: 2026-04-20

Detailed Transactions and Holdings:

• Sold 328,000 shares of Ordinary Shares at $465.1067 per share (Direct)
  Date: 2026-04-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,453,821.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 72,000 shares of Ordinary Shares at $466.0 per share (Direct)
  Date: 2026-04-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,381,821.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 50,000 shares of Ordinary Shares at $467.0 per share (Direct)
  Date: 2026-04-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,331,821.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 80,000 shares of Ordinary Shares at $471.0 per share (Direct)
  Date: 2026-04-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,251,821.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: New Taiwan Dollars.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $465 to $465.5 New Taiwan Dollars per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.